about
The ketogenic diet in a pill: is this possible?Nicotine as a potential neuroprotective agent for Parkinson's disease.Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease.Bee Venom Alleviates Motor Deficits and Modulates the Transfer of Cortical Information through the Basal Ganglia in Rat Models of Parkinson's Disease.The emerging role of proteolysis in mitochondrial quality control and the etiology of Parkinson's disease.Anti-N-methyl-D-aspartate receptor encephalitis: an emerging cause of centrally mediated sinus node dysfunction.Static posturography in aging and Parkinson's diseaseNewly Diagnosed Anemia Increases Risk of Parkinson's disease: A Population-Based Cohort StudyTranscranial brain sonography findings in Parkinson's disease: implications for pathogenesis, early diagnosis and therapy.Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease.How should we treat a patient with early Parkinson's disease?Safinamide in the treatment of Parkinson's disease.Mitochondrial pathology in Parkinson's disease.Early versus delayed initiation of pharmacotherapy in Parkinson's disease.Does MAP2 have a role in predicting the development of anti-NMDAR encephalitis associated with benign ovarian teratoma? A report of six new pediatric cases.Pramipexole reduces phosphorylation of α-synuclein at serine-129.Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis.Timed motor tests can detect subtle motor dysfunction in early Parkinson's disease.
P2860
Q33346385-E50EC17B-F04D-45C7-93FD-5B3582792F98Q34281003-E870698A-58BE-406D-8ADC-ADD97212ECCCQ35065682-F5FE05BF-7EAD-4301-B5A5-CD71C5813126Q35489240-53E41CF9-8EAC-4DCF-A2A0-1678F195921EQ35628604-205B0798-6BFD-4AA9-B84E-3B58B791CF38Q35842101-B60E286E-0C74-4BF4-9960-1FCC67032C1EQ35986574-A547C823-8BF8-4FE8-8CB5-DE25D067E8B8Q36114811-4F3B1568-22B5-4876-AD36-8317EFDC71F9Q36142216-E9F55948-5076-4542-94D9-790AED85015AQ37093196-2BC34759-1391-43B9-A450-AB5CBFB84A47Q37507963-65CC84B0-0A67-4E2B-A712-70B12FABFE77Q37669479-577B2AC1-ED6B-4CBE-9840-F7D30FEE6BE5Q37775098-7FEE2C73-98E2-4AA5-8E6F-D74C3766A0D1Q37779808-BA374E8C-643B-4FBC-827F-0332B99A6E40Q37954223-DD264EB3-5505-4A0B-BDBD-FB69E0178A16Q38206403-E6B55720-50A7-4138-A1D4-CA958F931FDBQ38311307-F622D67F-1050-4C8A-8CB7-8326FBD86936Q39150857-55AB7168-F479-49E5-B600-26ECEADD7322Q43489430-7B1B8390-912E-417D-B2DB-4CF0B207EF9DQ48128730-107BC6D0-5400-4B7E-B322-A10F27823EA3
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Progress in neuroprotection in Parkinson's disease.
@en
Progress in neuroprotection in Parkinson's disease.
@nl
type
label
Progress in neuroprotection in Parkinson's disease.
@en
Progress in neuroprotection in Parkinson's disease.
@nl
prefLabel
Progress in neuroprotection in Parkinson's disease.
@en
Progress in neuroprotection in Parkinson's disease.
@nl
P2860
P1476
Progress in neuroprotection in Parkinson's disease.
@en
P2093
A H V Schapira
P2860
P356
10.1111/J.1468-1331.2008.02055.X
P478
15 Suppl 1
P577
2008-04-01T00:00:00Z